DNA methylation-based classification of central nervous system tumours D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ... Nature 555 (7697), 469-474, 2018 | 2295 | 2018 |
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor CA Opitz, UM Litzenburger, F Sahm, M Ott, I Tritschler, S Trump, ... Nature 478 (7368), 197-203, 2011 | 1867 | 2011 |
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial W Wick, M Platten, C Meisner, J Felsberg, G Tabatabai, M Simon, ... The lancet oncology 13 (7), 707-715, 2012 | 1218 | 2012 |
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood M Weller, M van den Bent, M Preusser, E Le Rhun, JC Tonn, G Minniti, ... Nature reviews Clinical oncology 18 (3), 170-186, 2021 | 1161 | 2021 |
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond M Platten, EAA Nollen, UF Röhrig, F Fallarino, CA Opitz Nature reviews Drug discovery 18 (5), 379-401, 2019 | 962 | 2019 |
Brain tumour cells interconnect to a functional and resistant network M Osswald, E Jung, F Sahm, G Solecki, V Venkataramani, J Blaes, S Weil, ... Nature 528 (7580), 93-98, 2015 | 940 | 2015 |
Lomustine and bevacizumab in progressive glioblastoma W Wick, T Gorlia, M Bendszus, M Taphoorn, F Sahm, I Harting, ... New England Journal of Medicine 377 (20), 1954-1963, 2017 | 909 | 2017 |
A vaccine targeting mutant IDH1 induces antitumour immunity T Schumacher, L Bunse, S Pusch, F Sahm, B Wiestler, J Quandt, O Menn, ... Nature 512 (7514), 324-327, 2014 | 773 | 2014 |
Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 763 | 2019 |
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion M Platten, W Wick, BJ Van den Eynde Cancer research 72 (21), 5435-5440, 2012 | 745 | 2012 |
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions PY Wen, M Weller, EQ Lee, BM Alexander, JS Barnholtz-Sloan, ... Neuro-oncology 22 (8), 1073-1113, 2020 | 742 | 2020 |
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis F Sahm, D Schrimpf, D Stichel, DTW Jones, T Hielscher, S Schefzyk, ... The lancet oncology 18 (5), 682-694, 2017 | 731 | 2017 |
Aryl hydrocarbon receptor control of a disease tolerance defence pathway A Bessede, M Gargaro, MT Pallotta, D Matino, G Servillo, C Brunacci, ... Nature 511 (7508), 184-190, 2014 | 667 | 2014 |
MGMT testing—the challenges for biomarker-based glioma treatment W Wick, M Weller, M Van Den Bent, M Sanson, M Weiler, A Von Deimling, ... Nature Reviews Neurology 10 (7), 372-385, 2014 | 590 | 2014 |
Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite M Platten, PP Ho, S Youssef, P Fontoura, H Garren, EM Hur, R Gupta, ... Science 310 (5749), 850-855, 2005 | 524 | 2005 |
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for … DE Reuss, F Sahm, D Schrimpf, B Wiestler, D Capper, C Koelsche, ... Acta neuropathologica 129, 133-146, 2015 | 507 | 2015 |
Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM TV Lanz, RC Brewer, PP Ho, JS Moon, KM Jude, D Fernandez, ... Nature 603 (7900), 321-327, 2022 | 498 | 2022 |
SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro … M Uhl, S Aulwurm, J Wischhusen, M Weiler, JY Ma, R Almirez, ... Cancer research 64 (21), 7954-7961, 2004 | 487 | 2004 |
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate L Bunse, S Pusch, T Bunse, F Sahm, K Sanghvi, M Friedrich, D Alansary, ... Nature medicine 24 (8), 1192-1203, 2018 | 440 | 2018 |
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis B Wiestler, D Capper, T Holland-Letz, A Korshunov, A Von Deimling, ... Acta neuropathologica 126, 443-451, 2013 | 414 | 2013 |